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Abstract: The interruption of malaria transmission
worldwide is one of the greatest challenges for interna-
tional health and development communities. The current
expert view suggests that, by aggressively scaling up
control with currently available tools and strategies, much
greater gains could be achieved against malaria, including
elimination from a number of countries and regions;
however, even with maximal effort we will fall short of
global eradication. The Malaria Eradication Research
Agenda (malERA) complements the current research
agenda—primarily directed towards reducing morbidity
and mortality—with one that aims to identify key
knowledge gaps and define the strategies and tools that
will result in reducing the basic reproduction rate to less
than 1, with the ultimate aim of eradication of the parasite
from the human population. Sustained commitment from
local communities, civil society, policy leaders, and the
scientific community, together with a massive effort to
build a strong base of researchers from the endemic areas
will be critical factors in the success of this new agenda.
Introduction
The unacceptable health burden of malaria, and its economic
and social impacts on development, have made it a focal point of
the international development agenda, and the world has
embraced an ambitious plan for scaling up malaria control that
progresses towards country-by-country and regional elimination
and the ultimate goal of global eradication [1]. Over the past
decade, resources and control efforts have intensified to a level not
seen since the early days of the World Health Organization’s
Global Malaria Eradication Program (GMEP) in the late 1950s.
Nonetheless, in 2009, with 3.28 billion people living in areas that
have some risk of malaria transmission and about 1.2 billion
people (one-fifth of the world’s population) living in areas with a
high risk of transmission (more than one reported case per 1,000
population per year), there were about 225 million cases of clinical
malaria and 781,000 malaria-related deaths. Today, there is
ongoing malaria transmission in 106 countries. Eighty-one of these
countries are focusing on control, while 25 are in pre-elimination,
elimination, and prevention of reintroduction phases; Morocco,
the United Arab Emirates, and Turkmenistan have recently been
certified as malaria free [2–4].
These statistics emphasize the direness of the current malaria
burden but also benchmark the accomplishments and progress
that have been achieved in malaria control. Following declarations
at the Malaria Forum in October 2007 convened by the Bill &
Melinda Gates Foundation, and subsequent support voiced by the
World Health Organization (WHO), the Roll Back Malaria
(RBM) Partnership, and many other organizations and institu-
tions, the paradigm of malaria control and elimination has been
extended to encompass an ultimate goal of malaria eradication
[1,2,5]. The question is no longer whether international agencies
and national health authorities should be mobilized to pursue the
goal of malaria eradication, but rather when and how.
A key question, however, is whether elimination from all regions
of the world (eradication) is feasible with the current tools and state
of knowledge. For a number of reasons, we believe that the answer
is ‘‘no.’’ First, malaria is not a single disease. The five Plasmodium
species (falciparum, vivax, ovale, malariae, knowlesi) that cause human
malaria are transmitted by more than 30 Anopheline mosquito
species with diverse breeding and feeding habits, and result in
different disease spectra in different population target groups and
epidemiological settings. Second, current malaria control and
elimination programs face remarkable heterogeneity of transmis-
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sion dynamics of malaria in endemic areas, including differences in
parasite, vector, human, social, and environmental factors. Third,
operational limitations include underperforming health services,
lack of political will, insufficient financial, social and human
resources, and for some areas, inadequate tools to interrupt
transmission given an exceedingly high force of transmission. Each
country presents different combinations of these problems and
their determinants. Thus, a widely held view suggests that with
currently available tools, much greater gains could be achieved,
including elimination from a number of countries and regions, but
that even with maximal effort we will fall short of elimination in
many areas and of global eradication [6]. For definitions of terms
used regarding malaria eradication see Box 1.
Mixed Success and Failure of Past Malaria Control
and Elimination Efforts
A detailed discussion of all the factors involved in the partial
success of the past eradication campaign is beyond the scope of
this introduction, but three critical elements can be highlighted.
First, there was insufficient recognition of the heterogeneity of
malaria transmission and disease. Much of the optimism that
inspired WHO GMEP in 1955 was based on the successful
outcomes of earlier control programs that benefited from a
combination of biological, parasitological, social, and environ-
mental factors that favoured success (e.g., the rarity of DDT-
resistant Anophelines and of chloroquine-resistant parasites).
Second, the first WHO GMEP (1955-1969) was predicated on
an assumption that the available knowledge and tools were
sufficient to achieve worldwide eradication. A single strategy that
would work everywhere—‘‘one size fits all’’—proved to be ill-
founded because it underestimated the challenges of dealing with
the extremely efficient vectors in Africa (An. gambiae) and with
transmission by outdoor-feeding mosquitoes that were not
susceptible to attack by indoor residual insecticide. It also did
not allow for the lack of safe drugs for mass administration to
remove all infectious parasites from symptomatic and asymptom-
atic carriers, particularly from people carrying P. vivax or P. ovale,
species that establish latent liver infections that are responsible for
relapses months or years following initial infection. Third,
insufficient research in biomedical and social sciences and
inadequate local application of research findings across a wide
variety of settings are widely viewed to have contributed to
demoralization and waning effort when tools proved ineffective or
could not be adequately implemented. The neglect of malaria
research during and after the campaign did long-term damage.
These elements resulted in a lack of progress that in turn
compromised continued financial support [7].
Current Malaria Control Efforts: The Goal of
Eradication and Its Research and Development
Implications
The past decade has witnessed renewed investment in malaria
control and substantial increases in funding for malaria research.
The Roll Back Malaria Global Malaria Action Plan (GMAP) and
WHO have recently revised and updated the strategy and the steps
for scaling up and sustaining malaria control (Figure 1). In
addition, the Malaria Elimination Group (MEG), a group of
scientists, public health decision makers, control program
managers, and funders, has compiled a guide to policy makers
for areas that embark or have embarked on elimination strategies
[8].
Reductions in disease incidence are being documented, even in
some areas of sub-Saharan Africa that constitute the heartland of
malaria transmission [2]. There are, however, significant threats to
current progress that cannot be ignored, and unmet needs that will
continue to be central to the global research agenda for improving
malaria control and eventually achieving eradication. Notable
examples are the emergence of artemisinin resistance and the
consequent need for improved strategies to contain dissemination
of resistant parasite strains coupled with accelerated research into
potential new drugs for first-line treatment [9,10]. Similarly, new
insecticides are urgently needed to replace those threatened by
increased mosquito resistance [11], and accelerated development
of vaccines that can impact on malaria incidence, disease, and
death remains a high priority [12].
Complementing the current research agenda—primarily directed
towards improving malaria control and reducing morbidity and
mortality—with research on developing tools, interventions, and
strategies to interrupt transmission and ultimate eradication of the
parasite from the human population constitutes a true paradigm shift.
Box 1. Clarifying the Goals and Definitions
N Control: Reduction of disease incidence, prevalence,
morbidity, or mortality to a locally acceptable level as a
result of deliberate efforts; continued intervention
measures are required to maintain the reduction.
N Elimination: Reduction to zero of the incidence of
locally transmitted malaria infection in a defined
geographical area as a result of deliberate efforts;
continued intervention measures are required to prevent
reestablishment of transmission.
N Eradication: Permanent reduction to zero of the global
incidence of malaria as a result of deliberate efforts;
intervention measures are no longer needed [1].
N What species? Although the eradication of P. falci-
parum, the most serious form of malaria, would
constitute an historic public health achievement, the
coexistence of transmission of P. falciparum and P. vivax
in many areas of the world together with the fact that
they are the species responsible for the major burden of
disease, make it necessary to aim for the eradication of
both.
Summary Points
N Malaria remains a major global public health problem,
but a recent paradigm shift has moved the emphasis
from control of malaria to the interruption of malaria
transmission and ultimately malaria eradication
N The Malaria Eradication Research Agenda (malERA)
initiative was convened in 2008 to define the knowledge
base, strategies, and tools required to eradicate malaria
from the human population
N A two-year consultative process has resulted in the
preparation of a detailed research and development
agenda for malaria eradication, which is reported in this
Supplement
N Implementation of this research agenda might enable
the elimination of malaria, even in the most difficult
areas
N However, to achieve the aim of malaria eradication in a
timely manner, commitment to implementing this
agenda must begin immediately
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The malERA Initiative
To catalyze this paradigm shift towards malaria elimination and
eradication, it was necessary to design a process to bring together
the best scientific minds in the malaria community. That process is
the Malaria Eradication Research Agenda (malERA) initiative,
which was established to complement GMAP and which aims to
define the critical knowledge base, strategies, and tools required to
reduce the basic reproduction rate (R0 or the number of secondary
cases arising from a single case) to less than one.
Scientists involved in malaria research were challenged to develop
a multidisciplinary, global research and development agenda that
would be actionable by research and public health agencies and
funders/sponsors and available for discussion and debate through
publication in a readily accessible format. The process engaged more
than 250 scientists in a series of 20 consultations around the world
(Figure 2) and was managed by a three-tier governance structure
(Figure 3). The rest of this article briefly introduces the work
undertaken by the various malERA Consultative Groups and
presented in the other articles in this Supplement.
Tools to Interrupt Malaria Transmission
To reduce the basic reproduction rate to less than 1, and hence
to interrupt transmission, interventions are needed to reduce the
reservoir of infection, the time that a person or a mosquito is
infectious, and the rate at which infections are spread. This goal
can be achieved by drugs or vaccines directed against the parasite
or by new tools that attack the vector, with the support of
improved diagnostics and surveillance.
Drugs: Single Encounter Radical Cure and Prophylaxis
In the recent past, drug development efforts were guided by the
need for first-line drugs to treat P. falciparum infections with an
increasing emphasis on drugs with a short half-life that potentially
minimize the risk of development of resistance rather than on
drugs with a long half-life that have benefits for dosing and post-
treatment prophylaxis [13]. Treatment of infected individuals with
a variety of drug regiments has been used successfully in
combination with intensive vector control to eliminate malaria
from areas with relatively strong health systems and stable
populations. However, interruption of malaria transmission is
likely to require a new set of drugs and formulations.
As described in more detail in the article by the malERA
Consultative Group on Drugs [14], such drugs will need to be used
both in stable transmission areas and in complex urban or remote
rural areas, with poorly functioning health systems where concerted
campaigns may be the only way of achieving high coverage or
preventing reintroduction by migrants or travelers from endemic
regions. For such campaigns to impact effectively on inaccessible
populations, a single encounter between health providers and
target populations is critical. Single Encounter Radical Cure and
Prophylaxis (SERCaP) has a target product profile (TPP) that
includes radical cure, defined as elimination of all parasites (including
the long-lived hypnozoites of P. vivax or P. ovale in the liver), suitability
for mass administration (including administration to healthy sub-
jects and the consequent need of a very good safety profile), and
prophylaxis for at least 1 month after treatment, to outlast the typical
development period of Plasmodia parasites in Anopheline mosquitoes.
A drug with this profile would perform in a similar way to a highly
efficacious pre-erythrocytic (infection-preventing) vaccine.
A drug with this TPP may take a long time to develop, but the
development of new drugs that meet some of these essential
requirements could dramatically improve chances of eradication.
For example, development of new safe and effective drugs that block
the infectivity of the mature sexual forms of P. falciparum gametocytes
and/or the dormant hepatic forms (hypnozoites) of P. vivax could have
a profound impact on transmission rates and would be valuable tools
in the efforts to contain and eliminate parasite strains resistant to first-
line treatment drugs. Presently, only the 8-aminoquinolines are
known to be effective against both P. vivax hypnozoites and P.
falciparum stage-five gametocytes. Unfortunately this class of drugs has
significant side-effects in some individuals, particularly hemolysis in
those with G6PD deficiency, that compromise their widespread use in
mass administration for elimination [14].
Vaccines that Interrupt Malaria Transmission
Vaccines currently in clinical development have the primary aim
of reducing morbidity and mortality from P. falciparum in young
children living in highly endemic countries. However, with the new
goal of elimination and eradication, vaccines that will reduce and
contribute to interruption of transmission also need to be developed.
The broader concept of ‘‘vaccines that interrupt malaria transmis-
sion (VIMT)’’ is introduced by the malERA Consultative Group on
Vaccines to replace the term ‘‘transmission blocking vaccines’’
(TBVs), which has been used widely to refer to vaccines that target
only the sexual and mosquito stages of the parasite [15]. VIMT
could include antivector vaccines that target mosquito molecules
essential for parasite development, highly effective pre-erythrocytic
or erythrocytic stage vaccines, and vaccines targeting parasite
antigens of sexual and mosquito stages of the infection. The desired
TPP identified by the Consultative Group for VIMT indicates that
they should be effective against both P. falciparum and P. vivax, suitable
for administration to all age groups, and should impact transmission.
Other issues discussed by the group in their article include the need
Figure 1. Epidemiological milestones [1,23]. Image credit: Fusio´n Creativa.
doi:10.1371/journal.pmed.1000406.g001
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for validated functional assays that measure the reduction in
infectivity at the individual level after vaccination that could be
used as surrogate measures to predict reductions in transmission
rates at the community level. Such surrogate measures will be critical
components of a regulatory pathway leading to licensure. Standard-
ized, specific and sensitive methods for assessment of transmis-
sion rates, particularly when intensity is low, will be critical in the
assessment of vaccine efficacy in interrupting transmission following
large-scale deployment of vaccination as an elimination tool [15,16].
Vector Control
The overarching goal of vector control is to reduce the vectorial
capacity of local vector populations below the critical threshold to
prevent ongoing or epidemic transmission. Because it takes a
relatively long time (days) after ingestion for Plasmodia to become
infective to humans in its Anopheles vectors, the most effective
vector control strategies currently in use rely on interventions like
indoor residual insecticide spraying and insecticide treated bednets
(ITNs) that reduce vector daily survival rates [17].
The malERA Consultative Group on Vector Control identifies
three critical challenges in its article [18]. The most pressing
challenge is the development of a coherent research agenda for
discovering and developing a broader range of insecticides, with
novel modes of action that can circumvent emerging resistance to
existing insecticides, in particular, pyrethroid-based insecticides
[11]. The second challenge is the development of interventions that
affect vectors that do not rest or feed indoors and are therefore not
susceptible to current tools. The final critical challenge is the
development of novel approaches that permanently reduce the high
vectorial capacities of the dominant malaria vectors in sub-Saharan
Africa. Genetic control programs based on permanent reduction of
the vectorial capacities of natural vector populations have received
the most attention to date [19,20], but the Consultative Group also
considers the development of other novel approaches [18].
Diagnostics
Methods for measuring transmission are central to an
elimination agenda. Current methods for measuring transmission
that may be applied in endemic areas are time-consuming,
expensive, and too insensitive for use in conditions of low and
nonuniform infection [21,22]. Some years after regional elimina-
tion, as immunity declines, infection is likely to be symptomatic
and may become the best marker of resumed transmission.
However, during the early elimination phase in regions previously
experiencing high transmission, populations will retain clinical
immunity and will not experience symptomatic disease with every
infection [23]. Thus, the main challenge identified by the malERA
Consultative Group on Diagnoses and Diagnostics and discussed
in detail in their article and in the article on Cross-cutting Issues
for Eradication [24,25] is to find a robust, sensitive, and specific
standardized method for assessment of transmission intensity in
the intervening period when transmission continues at low and
nonrandom levels. Improved serological tests have been suggested
[26], but other minimally invasive biomarkers could be consid-
ered. This information will be essential for modeling potential
effects of various interventions alone, or in combination, and for
assessing efficacy of transmission–reducing vaccines and drugs.
Other challenges for diagnostics discussed by the Consultative
Figure 2. Consultative process towards a consolidated research and development agenda for malaria eradication. Image credit:
Fusio´n Creativa.
doi:10.1371/journal.pmed.1000406.g002
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Group include the need for tools that can rapidly detect and
monitor unexpectedly high transmission that leads to outbreaks
and that can identify reintroduction of infections that may be
asymptomatic [16,24].
Beyond the Tools: Supporting Strategies and the
Knowledge Base
Modeling and Harmonized Data Systems
Substantial advances have been made recently in computational
approaches for modeling malaria epidemiology and in model-
based approaches to economic evaluation [27–29]. As discussed by
the malERA Consultative Group on Modeling [16], a significant
research challenge for malaria eradication will be to integrate
these new approaches into the planning of elimination, surveil-
lance, monitoring, and evaluation, and to create appropriate
interfaces for different user communities, including researchers,
global and national policy makers, and local-level planners.
Modeling can inform the definition of TPPs for new tools and
intervention strategies and will be needed throughout a global
eradication campaign to analyze the likely effects on malaria and
of various elimination strategies and the costs of these strategies
[30].
Importantly, a single unifying model will be insufficient to meet
all these needs, so multiple modeling efforts need to be coordinated
and made accessible to everyone. This harmonization and
validation process will require close, iterative collaboration between
software engineers, researchers, and malariologists to develop the
necessary computer systems and connectivity (cyberinfrastructure).
It will also necessitate the creation and maintenance of properly
annotated and accessible malariometric databases that include all
the research results needed to insert parameters into the models and
the model outputs. How this can be achieved is considered in detail
by the Consultative Group in their article [16].
Enabling Technologies and Platforms
The development of new tools for elimination is critically
dependent on a vibrant and coherent agenda for basic sciences.
We believe there are at least two potentially transformative
developments that need to be pursued. First, continuous
laboratory culture of P. vivax, P. ovale, and P. malariae needs to be
developed to provide an essential platform for studying the biology
of the liver stages and sexual forms of these parasites. These forms
could be important targets of intervention strategies with drugs,
vaccines, or other biological or chemical agents aimed at
interrupting transmission. Second, systems analyses of transcrip-
Figure 3. The malERA governance bodies. Image credit: Fusio´n Creativa.
doi:10.1371/journal.pmed.1000406.g003
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tion, proteome, and metabolome libraries, rapid screening of drug
libraries, high-throughput approaches to antigen identification,
and the functional definition of gene products are all feasible but
not yet fully exploited, but would bring important new tools to the
bench scientist and to field operations. These and other aspects of
enabling technologies and platforms are considered in detail in the
articles prepared by the malERA Consultative Groups on Basic
Science and Enabling Technologies and on Cross-cutting Issues
for Eradication [25,31].
Health Systems Integration, Operational
Research, and Effectiveness-Decay Analysis
The previous formal attempt at global eradication of malaria
(1955–1969) depended largely on vertical operations that often
bypassed health systems and their health services because it was
assumed that eradication operations could be run most efficiently
in this way. Many of the elimination efforts failed, because the
health systems failed, leading to a pessimistic view that malaria can
only be eliminated where economic progress, governance, and
efficient health systems are in place to support maintenance of
conditions necessary to block transmission [32,33].
It is now clear that the long-term solution to malaria elimination
and eradication will require a systems approach in which malaria-
specific interventions and actions are integrated into existing
health systems [34]. To achieve this, research is needed into health
systems, their readiness to optimize novel programs, systems, tests,
or other interventions, and their continuing performance [35–37].
During their deliberations, the malERA Consultative Group on
Health Systems and Operational Research identified the need for
a substantial research approach to establish and validate a tool kit
that allows effectiveness-decay analysis of health system impedi-
ments to effective and equitable coverage of malaria interventions
and that allows decisions to be made on the degree of possible
integration of interventions into an existing health system [16,38].
A further critical component of the research agenda identified by
this Consultative Group is the development and validation of a
decision-making framework to guide the move from control to
elimination.
Finally, but equally importantly, the article by the malERA
Consultative Group on Monitoring, Evaluation, and Surveillance
considers the need to investigate the performance of surveillance,
monitoring, and evaluation by new and old technologies [39,40] and
to evaluate optimal strategies for implementation of surveillance as an
active responsive intervention to further reduce transmission [41].
Training
The last time the world community tried to eliminate malaria,
so the joke goes, the only thing that was eliminated was
malariologists. For a renewed malaria eradication campaign to
Box 2. Key Examples of Critical Research
Needed to Support Elimination and
Eradication of Plasmodium falciparum and
Plasmodium vivax.
N In vitro culture and study of hypnozoites (persistent liver
stages) of P. vivax
N Drugs to be used for mass drug administration to clear
infections and provide prophylaxis to prevent new
infections
N Vaccines that target different stages of the parasite life
cycle, or the mosquito, with the key goal of interrupting
transmission
N New vector control approaches for (i) outdoor biting/
resting mosquitoes and (ii) achieving permanent reduc-
tions of vectorial capacity in areas where transmission is
predominantly due to the highly efficient vector A.
gambiae
N New approaches for fast and accurate assessment of
transmission at community level
N When to press the elimination button? Tool kits to
scientifically determine ‘‘health system readiness’’ for a
switch to elimination efforts
N New collaborative approaches to use of mathematical
modeling to inform TPPs, and expected outcomes of
mixes of intervention
N Strengthened monitoring and evaluation tools and
strategies for interrupting transmission that are linked
and embedded in the health and social systems
Figure 4. Key research and development issues and their position in relation to the different epidemiological phases towards
eradication. Image credit: Fusio´n Creativa.
doi:10.1371/journal.pmed.1000406.g004
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have a chance to succeed, it will be essential to train the
malariologists and scientists in the multiple disciplines needed for
an eradication campaign that might last 50 years, especially in
endemic countries. This need cannot be overemphasized. The
malaria research community remains small and often dominated
by the views and strategies of scientists who sit far away from the
problems. A massive effort to train, empower, and sustain research
capacity in the endemic countries will be a critical factor for the
success of improved control efforts and for the ultimate elimination
and eradication of malaria.
Concluding Remarks
The past 2 years have reinvigorated an old malaria paradigm in
which reduction of transmission is the driving strategy for malaria
interventions. The malaria community has now used the malERA
process to propose a research and development agenda that will be
essential for regional elimination and eventual global eradication
of malaria. Not every tool or strategy considered by the malERA
Consultative Groups (see Box 2) will be essential in every situation
(see Figure 4), but the complexity and heterogeneity, and in some
places, the sheer intensity of transmission, demand that we start
without delay to prepare for the most difficult challenges. This
focus on the end goal of eradication must not displace our
determination and efforts to continue to scale up ongoing efforts
for control and to include a research agenda for reducing
morbidity in areas of continuing moderate or high transmission.
Rather, it must encourage us to supplement our efforts with a
structured agenda that can realize the ultimate goal of eradication
envisaged by the Global Malaria Action Plan and the Roll Back
Malaria Partnership. An important lesson we can learn from other
disease elimination efforts is that complacency is dangerous. The
parasite and the vector are always evolving, and the human
environment is always changing. Thus, new research questions will
continually arise during the course of elimination [42], and active
malaria research, particularly on the development of new tools,
must continue up to the point when eradication is finally achieved.
We anticipate that the results of research efforts proposed by our
Consultative Groups for each stage of progression, from scaling up
for improved control to the elimination phases, will have great
synergy in design and application.
Past efforts at disease eradication, successful or otherwise, have
highlighted the importance of sustained commitment from local
communities, civil society, policy leaders, and the scientific
community to implement research in the context of the desired
integration of services, sector wide approaches, harmonisation of
activities, and long-term funding commitment. Thus, research
areas such as social science or research into direct and indirect
economic benefits of malaria eradication also need to be
strengthened. With these drivers in place, and the development
of the new tools we describe briefly here and in the other articles in
this Supplement, it may be possible to fulfil the dream that malaria
eradication can be achieved within the lifetime of young scientists
just embarking on their careers, even in the most difficult areas
where current tools/strategies have proven to be insufficient. The
time course may be long, but to have a chance of realizing that
dream, the commitment to starting those research and develop-
ment efforts must begin now.
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KM RDN CVP MHR RES LS MT.
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